Wellvana announced that Jim Murray has been appointed President and Chief Financial Officer, effective immediately. In this role, Murray will oversee the company’s financial and operational functions as Wellvana continues to expand its support for hospitals and providers participating in value-based care models nationwide. Murray brings over 40 years of experience in healthcare leadership spanning payer, provider, and service organizations. Most recently, he served as Chief Executive Officer of VillageMD, where he managed primary care operations for more than 200 clinics and 500,000 patients, including 150,000 Medicare beneficiaries in value-based arrangements, while also overseeing multispecialty and urgent care services.
Health Technology Insights: Nemluvio Shows Rapid Itch Relief and Sleep Benefits
Susan Diamond, Chief Executive Officer of Wellvana, said that Murray’s extensive leadership experience and proven ability to improve outcomes in value-based care will be critical as the company delivers innovative total cost of care strategies and drives growth, enhancing value for partners and the more than 800,000 beneficiaries they serve. Prior to VillageMD, Murray held senior roles at Centene and Magellan Health and spent over 28 years at Humana, where he led growth initiatives and operational transformation across Medicare, Medicaid, and commercial lines of business.
Health Technology Insights: Form Health Offers Clear, Predictable GLP-1 Coverage for Employers
Murray stated that he is eager to join Wellvana’s team, praising the company’s culture for empowering providers to succeed in value-based care. He emphasized his focus on improving cost, quality, and access while keeping patients at the center of every decision. The appointment comes after Wellvana’s recent milestones, including Susan Diamond’s promotion to CEO and the company’s accountable care organizations generating more than $337 million in Medicare savings for the 2024 Medicare Shared Savings Program, solidifying Wellvana’s position as a leading value-based care enabler for hospital- and rural-led ACOs.
Health Technology Insights: FDA Approves Exdensur (Depemokimab) for Severe Asthma
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
